Drugs / Anti-MUC1 CAR-T cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03706326 | Sep 2018 → Sep 2021 | esophageal cancer | The First Affiliated Hospital of Guangdong Pharmaceutical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02617134 | Nov 2015 → Nov 2017 | colorectal carcinoma, gastric carcinoma, malignant glioma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02587689 | Oct 2015 → Oct 2017 | hepatocellular carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-MUC1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02617134 ↗ |
| Action | Deplete | “allow the cells to identify and kill the MUC1+ tumor cells” NCT02587689 ↗ |
| Modality | Cell therapy | “autologous T cells bearing chimeric antigen receptor” NCT02587689 ↗ |
| Route | Other | “by infusion” NCT02617134 ↗ |
| Target | MUC1 | “chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1” NCT02587689 ↗ |